Page 69 of 73
Animal Health News & Notes for March 30, 2001
**************************************************************** Brakke Consulting’s Animal Health News & Notes for March 30, 2001 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > Neogen Corporation announced a 37% increase in quarterly revenues, and earnings that met analyst expectations. Neogen reported earnings of $0.12 per share for the third quarter, which ended Feb. 28, as compared with $0.11 for the same period last year. Third quarter revenues were $8.6 million in fiscal year 2001 compared to $6.3 million in FY 2000. Year-to-date revenues were $25.7 million, a 51% increase over the prior year comparable revenues of $17.0 million. The Company’s Animal Safety Division saw a 34% increase in revenues for the third quarter, and stood at a 50% increase on a year-to-date comparison. Year to date, Neogen’s FY 2001 earnings were $0.39 per share, as compared to $0.30 for the first nine months of last year. In its third quarter, Neogen continued its strong improvement in income from operations, increasing 29% on a quarter-to-quarter comparison with the previous fiscal year. Year to date, Neogen’s operating income was $2.9 million, a 74% increase from the prior year’s $1.7 million at the end of the third quarter. (PRNewswire) > IGI Inc. reported a net loss of $11.4 million for the year ended December 31, 2000, compared to a net loss of $1.6 million in
;
March 30, 2001
Animal Health News & Notes for March 23, 2001
**************************************************************** Brakke Consulting’s Animal Health News & Notes for March 23, 2001 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > Bayer reported full year 2000 sales for its animal health group were 999 million euros ($941 million), an increase of 8.9% over 1999. (company website) > Tyson Foods, Inc. revised its earnings outlook for the second quarter, ending March 31, 2001, saying it now expected earnings to be at or near break even. This compares with the $0.06 to $0.10 that the Company had projected earlier. Second quarter earnings will include charges relating to the previously announced product recall and the divestiture of the North Carolina hog operation, amounting to approximately $0.02 to $.03 per share. Additionally, the on-going effect of the severe winter weather has been worse than previously anticipated, and is expected to reduce earnings another $0.03 to $0.04 per share. Higher grain costs, energy costs and weaker than expected pricing recovery are also contributing to the earnings shortfall. (PRNewswire) **************************************************************** Company News Releases > Heska Corporation announced that it has entered into a distribution agreement with Novartis Animal Health Canada, Inc., granting Novartis exclusive distribution rights for the sale of the HESKA’s Flu Avert I.N. vaccine in Canada. Financial terms of the agreement were not disclosed. Novartis Animal Health is expected to sell Flu Avert
;
March 23, 2001
Animal Health News & Notes for March 16, 2001
**************************************************************** Brakke Consulting’s Animal Health News & Notes for March 16, 2001 Copyright © Brakke Consulting, Inc. **************************************************************** Company News Releases > LION bioscience AG announced that Intervet has extended its collaboration with LION for its bioinformatics solutions. The contract consists of extended licenses for the data integration technology SRS and the automated gene and genome annotation system bioSCOUT, as well as for new licenses to LION’s novel genome comparison software genomeSCOUT and SRS everEST, a soon-to-be-launched product for EST clustering. (PRNewswire) > Bayer announced that it is distributing Kiltix Topical Tick Control for Dogs, free to veterinarians to distribute to dog owners who purchase Advantage. Bayer recommends that the product be administered once a month to control ticks. The product should not be used on cats. (Veterinary Practice News) > Dr. Brendan Fox, president of Elanco, announced his retirement effective March 31, 2001. Dr. Fox’s career with Elanco spanned over 20 years, and included a variety of assignments in sales and marketing management, both in the US and overseas. Dr. Fox was appointed president of Elanco in 1990. Pat James has been announced as Dr. Fox’s successor. (Feedstuffs) > Tyson issued the following statement regarding IBP: We are pleased that IBP continues to make progress resolving its outstanding issues with the Securities and Exchange Commission. However, the non-cash impairment
;
March 16, 2001
Animal Health News & Notes for March 9, 2001
**************************************************************** Brakke Consulting’s Animal Health News & Notes for March 9, 2001 Copyright © Brakke Consulting, Inc. **************************************************************** Company News Releases > Intervet has chosen its site in DeSoto, Kansas, for the construction of a state-of-the-art facility that will serve as the regional R&D, production and administrative center in the Mid-west of the USA. The total investment will amount to $37 million. Following its recent acquisitions of Hoechst Roussel Vet, Bio-Trends International and Bayer’s North American biologicals business, Intervet currently operates 12 locations in the US. The completion of the new integrated facility in DeSoto will significantly streamline U.S. operations by enabling the number of US core sites to be reduced to a total of three: DeSoto (Kansas), Millsboro (Delaware), and Worthington (Minnesota). (AnimalNet) > The FDA is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Novartis Animal Health US, Inc. The supplemental NADA provides for veterinary prescription use of milbemycin oxime solution to treat ear mite infestations in cats and kittens 4 weeks of age and older and for a repeat treatment, if necessary. (AnimalNet – Federal Register) > Heska Corporation announced that it has obtained marketing rights to a new product for the detection of Giardia and Cryptosporidium from Genzyme Corporation. The agreement grants to Heska broad rights
;
March 9, 2001
Animal Health News & Notes for March 2, 2001
**************************************************************** Brakke Consulting’s Animal Health News & Notes for March 2, 2001 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > Aventis reported full year 2000 sales for Merial rose 10.5% (+1.1% excluding currency effects) to € 1.74 billion ($1.64 billion) from € 1.58 billion ($1.49 billion) in 1999. (company website) > Akzo Nobel reported that for the full year 2000, Intervet turned in an excellent performance with sales of EUR 1.02 billion ($960 million). The year was dominated by the integration of the Hoechst Roussel Vet businesses acquired in 1999. The strong position of Intervet in the global animal healthcare market was further enhanced by recent acquisitions, including Bayer’s Biologicals in the United States. (company website) > Alpharma reported financial results for the fourth quarter and year ended December 31, 2000. The Animal Pharmaceuticals division (composed of the Animal Health and Aquatic Animal Health divisions) reported revenues for the fourth quarter 2000 of $101.3 million, an increase of 84% over the fourth quarter. Increases were primarily due to acquisition of Roche’s medicated feed additives business in 2000. Operating income increased to $19.6 million for the quarter. For the full year, revenues increased 82% to $319.6 million. Operating income increased 64% to $58.3 million. (PRNewswire) > Aventis Animal Nutrition reported results for the year ended December 31, 2000.
;
March 2, 2001
Animal Health News & Notes for February 23, 2001
**************************************************************** Brakke Consulting’s Animal Health News & Notes for February 23, 2001 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > IDEXX Laboratories, Inc. reported net income of $9.8 million for the quarter ended December 31, 2000, compared to net income of $8.8 million for the fourth quarter of 1999. Revenue for the three months ended December 31, 2000, increased to $91 million from $89 million for the same period in 1999. For the year ended December 31, 2000, net income was $36.6 million compared to net income of $32.6 million for the prior year. Revenue for 2000 increased to $367 million from $358 million in 1999. (company website) > Heska reported financial results for the fourth quarter and year ended December 31, 2000. For the year, total revenues increased by 3% to $52.7 million. Product revenues from the company’s continuing core business increased 26%, attributable to strong growth in veterinary medical instrument products and increases in other product lines. The company’s Diamond Animal Health subsidiary also posted solid revenue growth. The company’s net loss for the year was ($21.9) million, a 39% improvement over 1999. In the fourth quarter of 2000, total revenues declined by 20% to $11.4 million, primarily due to soft sales in the Diamond Animal Health subsidiary and the effect of businesses sold and discontinued
;
February 23, 2001
Animal Health News & Notes for February 16, 2001
**************************************************************** Brakke Consulting’s Animal Health News & Notes for February 16, 2001 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > Novartis reported results for the year 2000. Animal Health sales were CHF 1,083 million ($672 million), an increase of 17% over 1999 (9% increase in local currencies). Interceptor and Fortekor posted solid growth, and the farm animal business grew overall driven by Tiamulin sales. The acquisitions of Vericore, the Biostar product range, and Cobequid also made important contributions to sales. 2000 Operating income for the Animal Health group were CHF 179 million ($111 million), a decrease of 17% from 1999. The decline was attributed to one-time acquisition and separation costs and product-mix changes. Increase in research and development increased from 7% to 8% of sales. (company website) > Eli Lilly reported that sales for animal health division Elanco in the fourth quarter 2000 were $197.3 million, an increase of 3% compared with the fourth quarter of 1999. For the full year of 2000, animal health sales increased 6% to $668.5 million. Excluding the effect of exchange rates, sales grew by 7% for the quarter and 10% for the year. (company website) > Pharmacia reported sales for the animal health division were $118 million in the fourth quarter of 2000, a decrease of 9% from the comparable period in
;
February 16, 2001
Animal Health News & Notes for February 9, 2001
**************************************************************** Brakke Consulting’s Animal Health News & Notes for February 9, 2001 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > 2000 was a record-setting year for Veterinary Pet Insurance. Policy sales soared during the year marking the new millennium. In 2000, VPI issued more than 157,000 policies, an increase of 36% over 1999. Premiums for 2000 increased by 49.5% over 1999 proving that pet owners are opting for the most comprehensive insurance packages available. VPI processed 40.3% more claims in 2000 than in 1999. VPI expects to generate $50 million in revenue this year. (company press release) > Central Garden & Pet Company announced its financial results for the fiscal first quarter of 2001, ended December 30, 2000. Net sales for the first quarter were $213.3 million compared with $219.1 million in the comparable fiscal 2000 period. The Company recorded a net loss for the quarter of $4.5 million compared with a net loss of $6.5 million in the comparable year-ago period. Central typically shows a loss in the three-month period ending in December, which is the slowest time of the year for the garden industry. (Business Wire) > Draxis reported Companion Animal Health revenues for the fourth quarter of 2000 derived from the Company’s collaboration agreement with Pfizer with respect to Anipryl were $C 3.9 million ($US
;
February 9, 2001
Animal Health News & Notes for February 2, 2001
**************************************************************** Brakke Consulting’s Animal Health News & Notes for February 2, 2001 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > Tyson Foods, Inc. reported first quarter earnings were $27 million compared to $57 million for the same period last year. Total first quarter sales were $1.74 billion compared to $1.78 billion last year, a decrease of 2.0%. (PRNewswire) > The Procter & Gamble Company reported that Iams continued to exceed expectations in the second fiscal quarter ended December 31, 2000, as the expansion into new retail channels has delivered substantial growth, while the brand continues to be number one in pet specialty outlets. Specifics were not provided. (PRNewswire) > Colgate Palmolive reported that Hill’s increased fourth quarter sales and unit volume each by 5% in an impressive showing against the very strong year-ago period. Operating profit also rose in the quarter. Hill’s-U.S. increased consumption of Science Diet in the specialty retail channel, where its growth is outpacing category growth, and also enjoyed increased sales of Prescription Diet in the veterinary channel. New Science Diet products for Sensitive Skin and Sensitive Stomach in dogs and cats had a very successful sell-in, with national TV advertising beginning this month. The reformulation of the entire Science Diet line with a proprietary antioxidant formula drove growth as well. International growth was strong
;
February 2, 2001
Animal Health News & Notes for January 26, 2001
**************************************************************** Brakke Consulting’s Animal Health News & Notes for January 26, 2001 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > Pfizer reported fourth quarter sales of Animal Health were down 30% to $292 million, reflecting the size of the initial distribution of Revolution requested by veterinarians in the U.S. in the fourth quarter of 1999, competitive pressures on key brands, continuing weakness in U.S. and European livestock markets, and the negative impact of foreign exchange. Full-year 2000 animal health sales were $1,055 million, a decrease of 22% over 1999. (PRNewswire) > Schering-Plough reported fourth quarter sales of animal health products were up 14% to $216 million (23% when foreign exchange is excluded), with the increase primarily due to the June 2000 acquisition of the animal health business of Takeda Chemical Industries, Ltd. in Japan. Worldwide sales of animal health products in 2000 totaled $720 million, up 7% (12% when foreign exchange is excluded), primarily due to the June 2000 acquisition of the Takeda animal health business. (PRNewswire) > Ralston Purina Company announced first quarter earnings before unusual items of $81 million compared to pro forma earnings from continuing operations before unusual items of $89 million the prior year. Pro forma comparisons are necessary because Ralston spun off its Battery Products business on April 1, 2000. First quarter sales
;
January 26, 2001
Animal Health News & Notes for January 19, 2001
**************************************************************** Brakke Consulting’s Animal Health News & Notes for January 19, 2001 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > Cargill reported $174 million in earnings for the second quarter ended Nov. 30, up 20% from the same period a year ago. That brought earnings for the first six months of fiscal 2001 to $346 million, a 17% increase from last year’s first half. Second-quarter results continued to be led by Cargill’s beef processing business, and by its financial businesses, which delivered a balanced performance across geographies. Also highlighted was the company’s December acquisition agreement with Agribrands International, the maker and marketer outside the United States of Purina, Chow and other quality animal nutrition products. (AgWeb) > ABAXIS, Inc. reported record revenues for its third fiscal quarter and the nine-months ended December 31, 2000. For the third fiscal quarter, revenues increased 16% to $7.6 million compared with revenues for the same quarter last year. The Company reported a net loss of $561,000 compared to net income of $172,000 for the same quarter last year. The Company incurred one-time charges of approximately $1,033,000 and a non-recurring non-cash dividend of $1,418,000. Revenues for the nine-month period increased 38% to $22.0 million compared with revenues for the same period last year. The Company reported net income of $342,000 compared to a
;
January 19, 2001
Animal Health News & Notes for January 12, 2001
**************************************************************** Brakke Consulting’s Animal Health News & Notes for January 12, 2001 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > Neogen Corporation announced second quarter revenues jumped to $9.0 million, a 66% increase from last year’s second quarter. The quarter marked the first time the Company has exceeded the $9 million mark. Year-to-date revenues stand at $17.1 million, a 59% increase over the prior year comparable revenues. Neogen’s quarterly revenue increase was led by its Animal Safety Division, with a jump of 83% from the previous fiscal year. Of the Animal Safety increase, 28% can be attributed to the sales of comparable products from year to year, and the remainder to second-quarter sales of the recently acquired AmVet and Squire product lines. Year to date, Animal Safety sales are up 61%. (PRNewswire) **************************************************************** Company News Releases > As of January 4, the vitamins businesses of BASF and Takeda will be combined after approval by antitrust authorities in most countries. The combined business, owned by BASF, will have a global presence and a share of approximately 30% of the worldwide vitamins market. In Japan, the business will be organized as a joint venture for the sales and distribution of bulk vitamins, with BASF holding 66% and Takeda 34%. Outside Japan the combined product range will be the sole responsibility
;
January 12, 2001
Animal Health News & Notes for January 5, 2001
**************************************************************** Brakke Consulting’s Animal Health News & Notes for January 5, 2001 Copyright © Brakke Consulting, Inc. **************************************************************** NEW BRAKKE CONSULTING STUDY RELEASED Brakke Consulting announces the release of its newest syndicated study, The Current and Future Market for Small Animal Diagnostics in the USA. The study includes the following: – a review of the US diagnostics market – profiles of the leading US diagnostics companies – descriptions of the types of in-clinic diagnostics products currently available – discussion of potential areas of interest and technologies in development – veterinary opinions on current and desired in-clinic products – Brakke’s view of the future of veterinary diagnostics The study will be available January 15 for a price of $2,500. Please call (972) 243-4033 or email to info@brakkeconsulting.com (mailto:info@brakkeconsulting.com) for more information. **************************************************************** Company News Releases > Aventis Animal Nutrition has signed a definitive agreement to acquire Filozoo, the second-largest animal nutrition company in Italy. The two companies have worked together through joint ventures in Italy for 10 years. Financial terms were not disclosed. (Feedstuffs) > Tyson Foods announced that it has entered into a definitive merger agreement with IBP, Inc. Under the terms of the agreement Tyson will acquire all of the outstanding shares of IBP in a transaction valued at approximately $4.7 billion, which
;
January 5, 2001
Animal Health News & Notes for December 29, 2000
**************************************************************** Brakke Consulting’s Animal Health News & Notes for December 29, 2000 Copyright © Brakke Consulting, Inc. **************************************************************** Company News Releases > Idexx subsidiary Blue Ridge Pharmaceuticals has gained FDA approval for a new treatment for earmites in cats and kittens. ACAREXX is a 1% ivermectin suspension and is the company’s first prescription animal health product to be approved for sale. The product, administered topically in the ear canal, is approved for treatment of adult earmites. (Animal Pharm) > Biocor, a subsidiary of the Australian CSL group, has acquired the Herd-Vac bovine modified live virus vaccine range from Bayer. The Herd-Vac line of vaccines has been manufactured at the Biocor facility for several years. Biocor will now also assume distribution and marketing responsibility for the vaccine line. (Animal Pharm) > Tyson Foods Inc. has increased its bid for pork and beef processor IBP Inc. to $27 a share in cash and stock, or $2.8 billion. Tyson also offered $70 million as a breakup fee in case the deal hits antitrust obstacles. The offer comprises a cash component of 50.1% and the rest in stock. Tyson, which had earlier made a $26 per share bid. (E-markets – BridgeNews) > Tyson Foods Inc. is raising the stakes in the three-way battle with Smithfield Foods to take over IBP Inc. John Tyson,
;
December 29, 2000
Animal Health News & Notes for December 21, 2000
**************************************************************** Brakke Consulting’s Animal Health News & Notes for December 21, 2000 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > Animal health sales at Bayer grew 14% during the first three quarters of 2000. (Animal Pharm) > Central Garden & Pet Company announced its financial results for the fourth quarter and full year ended September 30, 2000. Full year net sales were $1.4 billion, compared with $1.5 billion in fiscal 1999. Central reported a net loss for fiscal 2000 of ($11.8) million, compared with a net income of $24.5 million in fiscal 1999. Excluding one-time charges associated with its discontinuance of its relationship with The Scotts Company, net income would have been $14.6 million. Net sales for the fourth quarter were $300.7 million, compared with $331.8 million in 1999. The net loss in the fourth quarter 2000 was ($30.3) million, compared with a net loss of ($4.3) million in the comparable period in 1999. Excluding one-time charges, net loss would have been ($3.9) million. (Business Wire) > Alcide Corporation announced net sales and earnings for its second fiscal quarter and half year ended Nov. 30, 2000. Net sales of $4.7 million for the quarter and $8.9 million for the half were the highest for any quarter or six-month period in Alcide’s history, and were 58% and 59% higher
;
December 21, 2000
Animal Health News & Notes for December 15, 2000
**************************************************************** Brakke Consulting’s Animal Health News & Notes for December 15, 2000 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > Biopure Corporation announced its financial results for the fourth fiscal quarter and fiscal year ended October 31, 2000. Total revenues were $920,000 for the fourth quarter of fiscal 2000, a 35% increase over the comparable period in 1999. Sales for the fiscal year were $3.1 million, compared to $2.9 million in 1999. The company reported a net loss of $6.8 million for the quarter, compared with a net loss of $10.0 million for the corresponding period in 1999. The company reported a net loss of $36.1 million for the year, compared with a net loss of $35.5 million for the same period in 1999. (PRNewswire) **************************************************************** Company News Releases > Pharmacia Corporation, the company formed in the merger between Pharmacia & Upjohn and Monsanto, announced that its animal health business will bear the name Pharmacia Animal Health. As part of a top tier pharmaceutical company, Pharmacia Animal Health will tap into the investment in research and development that Pharmacia makes each year. The Pharmacia Animal Health web site address will change to www.pharmaciaAH.com from Pharmacia & Upjohn Animal Health’s www.pnuanimalhealth.com. Both the new address and the former address will be operational, maximizing convenience for customers using the company’s
;
December 15, 2000
Animal Health News & Notes for December 8, 2000
**************************************************************** Brakke Consulting’s Animal Health News & Notes for December 8, 2000 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > PetQuarters, Inc. announced the financial results for the first quarter ending September 30, 2000. Revenues grew to approximately $4 million for the period compared to $2.5 million for the same period of a year-ago. Revenue growth can be attributed to an increase in sales through the Company’s website located at www.allpets.com as well as continued sales increases through the catalog division. Net operating loss for the quarter was approximately ($3.2) million as compared to ($1.26) million for the same period of the previous year. (PRNewswire) > Heinz reported results for the second quarter and first six months ended October 27, 2000. Pet Products revenues were $288 million in the second quarter, a decrease of 7% over the comparable period in the prior year. In the first six months, Pet Products sales were $564 million, a decrease of 6.6% over the prior year. (PRNewswire) **************************************************************** Sign up to attend Brakke Consulting’s 2001 Animal Health Industry Overview Inaugural presentations of the 2001 Overview will be open to general admission at two major upcoming veterinary conferences. – North American Veterinary Conference: Monday, January 15, 2001 9:30 am 1:30 pm – Western Veterinary Conference: Monday, February 12, 2001
;
December 8, 2000
Animal Health News & Notes for December 1, 2000
**************************************************************** Brakke Consulting’s Animal Health News & Notes for December 1, 2000 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > PETsMART, Inc. announced financial results for its third fiscal quarter ended October 29, 2000, and for fiscal 2000 year to date. The company reported a third quarter net loss of ($2.4) million, which includes a $6 million non-cash equity loss resulting from PETsMART.com adjusting certain balance sheet assets to current, realistic market values. As a result of its recent decision to acquire a controlling interest in PETsMART.com, PETsMART, Inc. is required to report 100% of those losses. Those results compare with a reported net loss of ($33.2) million for the same period last year. On a comparable basis, the company’s operating net income was $0.5 million or $0.00 per share. That compares with third quarter 1999 net operating income of $5.6 million or $0.05 per share, which excluded the equity loss on PETsMART.com and the loss from the sale of the United Kingdom subsidiary. Net sales for the third quarter were $541.3 million, compared to $511.8 million reported for the same period last year, while North American comparable store sales for the quarter increased 1.3%. As previously announced, results for the third quarter of 2000 were hurt by slowing sales in a difficult retail environment, and by higher-than-expected
;
December 1, 2000
Animal Health News & Notes for November 22, 2000
**************************************************************** Brakke Consulting’s Animal Health News & Notes for November 22, 2000 Copyright © Brakke Consulting, Inc. **************************************************************** Visit Brakke Consulting’s newly updated website at https://brakkeconsulting.com/! We’ve improved the site navigation, added a site search feature, and expanded our industry links page. You can also access the most up-to-date information about our syndicated studies, as well as descriptions of all our services. **************************************************************** Company News Releases > Oncolytics Biotech Inc announced that it has entered into a worldwide licensing agreement with US based pharmaceutical firm, Pfizer Inc., for the development and marketing of ONC’s reovirus for animal use. The reovirus has shown effectiveness in a number of animal model studies including canine. Pfizer will be responsible for development and commercialization of the product. ONC will provide continuing support to Pfizer for the development of the product. The terms of the agreement were not disclosed. (Business Wire) > AVANT Immunotherapeutics, Inc. announced that the company has entered into a definitive agreement to purchase privately held vaccine company, Megan Health, Inc. in a transaction valued at approximately $18 million. The transaction has been approved by the boards of directors of both companies and by a majority of Megan’s shareholders, and is expected to close shortly. The acquisition of Megan adds significantly to AVANT’s vaccine portfolio, giving the company a premier position in
;
November 22, 2000
Animal Health News & Notes for November 17, 2000
**************************************************************** Brakke Consulting’s Animal Health News & Notes for November 17, 2000 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > Tyson Foods, Inc. reported fourth quarter earnings for the fourth quarter ended September 30 were $18 million compared to $41 million for the same period last year. Total fourth quarter sales for fiscal 2000 were $1.78 billion compared to $1.82 billion last year, a decrease of 1.9%. Earnings for fiscal 2000 were $151 million compared to $230 million from the same period last year. Sales for fiscal 2000 were $7.16 billion compared to $7.36 billion last year, a decrease of 2%. The decrease in sales is mainly due to the sale of seafood and other non-core businesses during fiscal 1999. The results for fiscal 2000 were adversely affected by a $24 million charge related to the January 31, 2000, bankruptcy filing by AmeriServe. (PRNewswire) > Doane Pet Care Company reported net income of $1.6 million for its third quarter ended September 30, 2000 on net sales of $225.7 million, and net income of $4.6 million for the nine months ended September 30, 2000 on net sales of $640.9 million. The Company stated that results for the third quarter and nine months ended September 30, 2000 were not comparable to the reported results for the same fiscal 1999 periods
;
November 17, 2000
Page 69 of 73
English 
Portuguese 
Japanese 
Chinese